IDH1 and acute myeloid leukemia: The newly diagnosed AML cohort included patients aged ≥75 years with an IDH1 mutation who had comorbidities precluding the use of intensive therapy based on ≥1 of the following criteria: baseline ECOG PS ≥2, severe cardiac or pulmonary disease, hepatic impairment with bilirubin level >1.5 × ULN, or creatinine clearance <45 mL/min.47 Ivosidenib demonstrated a CR + CRi rate of 43% in patients with newly diagnosed AML; of these patients, 2 (7%) went on to receive HCT.47